Gregory Lewis is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
908 N Elm St Ste 404
Hinsdale, IL 605213638
Telephone
630-789-3422Provider last certified this registry record 22 Mar 2021.
Clinical trials
- EXercise and Activin Inhibition to Modulate InflammatioN Effects on Heart Failure and Cognition (EXAMINE-HFC)
Sponsor: Massachusetts General Hospital
- Mobile Monitoring of Fracture Healing
Sponsor: Milton S. Hershey Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
13 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- CVRx, Inc.Program year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20241 payment
- Impulse Dynamics (USA) Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
84.1%Statin22.1%Rosuvastatin Calcium73%Atorvastatin Calcium21%Pravastatin Sodium4%Simvastatin3%Part D≥392 patientsBeta blocker14.4%Metoprolol Succinate46%Carvedilol36%Metoprolol Tartrate9%Atenolol5%Sotalol2%Bisoprolol Fumarate2%Acebutolol Hcl1%Part D<11 patients+ 19 more classes in this area
Blood & clotting
12.6%Factor Xa inhibitor9.9%Eliquis80%Xarelto20%Part D≥181 patientsVitamin K antagonist1.4%Warfarin Sodium100%Part D≥33 patients+ 1 more class in this area
Metabolism & gastrointestinal
3.4%Potassium supplement2%Potassium Chloride100%Part D≥54 patientsSGLT2 inhibitor1.4%Jardiance100%Part D≥32 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”